SCHEMBL1132649

SCHEMBL1132649

CC(C)(C)OC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 3/20 0.57
ICAM1 P05362 3/20 0.57
ITGAL P20701 3/20 0.57
REN P00797 4/20 0.51
CA1 P00915 3/20 0.51
CA2 P00918 3/20 0.51
SLC6A5 Q9Y345 1/20 0.51
CYP3A4 P08684 2/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
SLC7A5 Q01650 1/20 0.49
ACE P12821 1/20 0.47
SLC15A2 Q16348 1/20 0.47
HRH3 Q9Y5N1 3/20 0.46
CPB2 Q96IY4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14028689 1.00 ITGB2 (0.57) ITGB2ICAM1ITGALRENCA1
SCHEMBL1133307 1.00 ITGB2 (0.57) ITGB2ICAM1ITGALRENCA1
SCHEMBL28684251 0.99 ITGB2 (0.56) ITGB2ICAM1ITGALRENCA1
SCHEMBL18878768 0.90 REN (0.49) ITGB2ICAM1ITGALRENCA1
SCHEMBL7438987 0.89 ITGB2 (0.54) ITGB2ICAM1ITGALRENCA1
SCHEMBL1486141 0.89 REN (0.49) ITGB2ICAM1ITGALRENHRH3
SCHEMBL18814494 0.89 REN (0.49) ITGB2ICAM1ITGALRENHRH3
SCHEMBL29290115 0.88 REN (0.55) RENSLC15A2
SCHEMBL7317825 0.88 REN (0.66) RENACE
SCHEMBL6806998 0.87 ITGB2 (0.62) ITGB2ICAM1ITGALCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117720617-A Synthesis process of acetyl tetrapeptide-3 山东济肽生物科技有限公司 2024-03-19 CN claimed
CN-117720471-A Preparation method of N-tert-butoxycarbonyl-L-histidine-N-trityl 成都普康唯新生物科技有限公司 2024-03-19 CN claimed
CN-115252806-A Preparation method of nano-drug carrier G5-R with high-efficiency tumor penetration capacity 浙江大学杭州国际科创中心 2022-11-01 CN claimed
CN-112791071-A Polymer micelle drug-loaded composition for aerosol inhalation and preparation method and application thereof 北京正隆医药研究院有限责任公司 2021-05-14 CN claimed
CN-104856973-A Cabazitaxel micelle drug load system and preparation method thereof SUZHOU LEINA PHARMACEUTICAL RES DEV CO LTD 2015-08-26 CN claimed
CN-102796170-B Double saturated aliphatic chain alcohol His-Gly-Lys-Asp tetrapeptide esters and preparation method and application thereof UNIV CAPITAL MEDICAL SCIENCES 2014-01-29 CN claimed
CN-102796171-B Double saturated aliphatic chain alcohol His-Gly-Glu-Asp tetrapeptide esters and preparation method and application thereof UNIV CAPITAL MEDICAL SCIENCES 2014-01-29 CN claimed
CN-102796170-A Double saturated aliphatic chain alcohol His-Gly-Lys-Asp tetrapeptide esters and preparation method and application thereof UNIV CAPITAL MEDICAL 2012-11-28 CN claimed
CN-102796171-A Double saturated aliphatic chain alcohol His-Gly-Glu-Asp tetrapeptide esters and preparation method and application thereof UNIV CAPITAL MEDICAL 2012-11-28 CN claimed
CN-101597291-A 2-(aminoacyl tryptophyl)-beta-tetrahydro carboline-3-benzyl carboxylate and its production and application UNIV CAPITAL MEDICAL (CN) 2009-12-09 CN claimed
US-12625431-B2 EUV resist underlayer film-forming composition NISSAN CHEMICAL CORPORATION (JP) 2026-05-12 US disclosed
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS PARDES BIOSCIENCES INC (US) 2026-04-30 US disclosed
US-12454771-B2 Substrates, peptide arrays, and methods VIBRANT HOLDINGS LLC (US) 2025-10-28 US disclosed
CN-118772440-B Preparation process and application of slow-release L-carnosine biological hydrogel 苏州富士莱医药股份有限公司 2025-03-11 CN disclosed
US-12145911-B2 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2024-11-19 US disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US disclosed
US-4757050-A Urea, amide group-containing E. R. SQUIBB SONS, INC. (US) 1988-07-12 US disclosed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP disclosed
CN-86105870-A Band 5-amino-2, the blood vessel tension peptide protoenzyme inhibitor of 5-two replacement-4-hydroxypentanoic acid bases 1987-03-11 CN disclosed
EP-0206313-A2 Chloro-substituted ketone imidazole derivatives G.D. Searle & Co. (US) 1986-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS CTRC, CTRL, CTSL ITGB2 2812/4885ICAM1 4087/4885ITGAL 2478/4885
US-12625431-B2 EUV resist underlayer film-forming composition EEF1A1, ARF1, EMG1 ITGB2 414/4885ICAM1 799/4885ITGAL 855/4885
US-12145911-B2 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL ITGB2 4458/4885ICAM1 3429/4885ITGAL 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.